Sei un medico?
Login
Registrati
You have now logged off
Login
Esci
CHI SIAMO
Le origini di Sanofi Pasteur
Una storia d'innovazione
Timeline
VACCINAZIONI
INFORMATI
• Come funziona l’immunizzazione
• Il valore della vaccinazione
• La produzione dei vaccini
PER ETÀ
• Neonati
• Bambini
• Adolescenti
• Future mamme
• Adulti e giovani
• Anziani
• Viaggiare ad ogni età
IN VIAGGIO
• Check-list di viaggio
• Sfatare i miti
• Consigli di viaggio
LE PATOLOGIE
INIZIATIVE
#PercheSì
Life
Meningococco
• Freedom
Influenza
• Resta connesso
• Non farti fermare
• PerchéSì Silver
Proteggersi
Superpoteri
NOTIZIE
CERCA UN CENTRO
HOME
VACCINAZIONI
PATOLOGIE
COVID-19
COMUNICATI STAMPA
INDIETRO
Comunicati stampa
May 27, 2021
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
May 17, 2021
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
March 12, 2021
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
February 22, 2021
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
December 11, 2020
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
October 28, 2020
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
October 15, 2020
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
September 22, 2020
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
September 18, 2020
Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
